<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this issue of Journal of Endocrinology, Dr Han and colleagues report a protective effect of the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> dehydrogenase activator 2-aminobicyclo-(2,2,1)-<z:chebi fb="1" ids="43098">heptane</z:chebi>-2-<z:chebi fb="1" ids="33575">carboxylic acid</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e>) under <z:mp ids='MP_0002055'>diabetes</z:mp>-like conditions that impair β-cell function in both a pancreatic β-cell line and db/db mice </plain></SENT>
<SENT sid="1" pm="."><plain>Based on these observations, the authors suggest that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e> could serve as a novel treatment modality in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The present commentary discusses the importance of the findings </plain></SENT>
<SENT sid="3" pm="."><plain>Some additional questions are raised, which may be addressed in future investigations, as there is some concern regarding the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e> treatment of β-cell failure </plain></SENT>
</text></document>